Windlas Biotech Reports June Quarter Revenue of 2.48 Bln Rupees

GURUGRAM — Contract development and manufacturing organization (CDMO) Windlas Biotech Limited reported its financial results for the first quarter ended June 30, 2026, posting a consolidated revenue from operations of 2.48 billion rupees. Disclosed through official stock exchange filings on August 10, 2026, the company logged a consolidated net profit of 176.5 million rupees for the three-month period. The earnings reflect continued demand across its pharmaceutical formulation services, trade generics, and over-the-counter (OTC) product portfolios.

Detailed Financial and Operational Performance

According to official filings submitted to stock exchange authorities, the June-quarter operational revenue of 2.48 billion rupees demonstrates sustained top-line growth driven by higher CDMO service volume and expanding commercial supply agreements.

The company registered a consolidated net profit of 176.5 million rupees, supported by operational efficiencies, steady raw material procurement, and capacity optimization across its manufacturing facilities in Dehradun, Uttarakhand. Operating profit margins remained healthy, aided by higher capacity utilization across newly integrated solid oral dosage and complex generic processing lines.

Corporate Profile and Strategic Industry Position

Headquartered in Gurugram with primary manufacturing hubs in Uttarakhand, Windlas Biotech Limited stands among the leading domestic pharmaceutical CDMO players in India. The enterprise provides end-to-end services ranging from dosage form development and regulatory licensing to commercial-scale manufacturing of generic formulations, liquid topicals, and specialized solid oral dosage forms.

The latest financial dispatch arrives as domestic and international pharmaceutical companies increasingly outsource formulation development to specialized CDMO partners to optimize capital efficiency and shorten commercial go-to-market timelines. Analysts note that Windlas Biotech's ongoing focus on high-margin complex generics and trade generic brand building positions the enterprise to capture expanding market share across domestic and emerging export markets.

Strategic Value for Investors and Industry Stakeholders

The first-quarter financial metrics offer transparency to institutional shareholders, retail investors, and commercial supply chain partners. Delivering 2.48 billion rupees in operational revenue reinforces execution capabilities amid shifting raw material cost dynamics in the global active pharmaceutical ingredient (API) market.

For institutional market participants, the firm's balance sheet discipline and low debt profile provide strategic flexibility to invest in specialized dosage technologies, including injectables and pediatric formulations, further strengthening its contract manufacturing pipeline.

Official Sources Section

Information regarding the financial metrics, consolidated operational revenue, and quarterly net profit is sourced directly from official corporate press statements and statutory financial disclosures filed by Windlas Biotech Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Documents were formally filed on August 10, 2026, with the National Stock Exchange of India Limited (NSE) and BSE Limited.

Quote Section

"According to officials and regulatory dispatches submitted by Windlas Biotech Limited to stock exchange authorities on August 10, 2026, the company's consolidated financial results reflect steady demand across its core CDMO and formulation manufacturing verticals during the quarter ended June 30, 2026."

Why It Matters

The strong top-line performance highlights the growing role of Indian CDMOs in the pharmaceutical value chain. As global and domestic brand owners prioritize lean supply chains and flexible manufacturing capacities, established formulation partners like Windlas Biotech provide essential infrastructure for affordable healthcare products and critical therapeutic treatments.

Key Facts at a Glance

• Consolidated Operational Revenue: 2.48 billion rupees for the quarter ended June 30, 2026.

• Consolidated Net Profit: 176.5 million rupees.

• Core Business Vertical: Pharmaceutical CDMO (Contract Development and Manufacturing Organization) services.

• Manufacturing Hubs: Integrated production facilities located in Dehradun, Uttarakhand.

• Filing Date: August 10, 2026.

FAQ Section

What was Windlas Biotech's consolidated revenue for the June quarter?

Windlas Biotech reported a consolidated revenue from operations of 2.48 billion rupees for the quarter ended June 30, 2026.

What was the company's net profit for the period?

The company registered a consolidated net profit of 176.5 million rupees for the June quarter.

What are the main business segments of Windlas Biotech Limited?

Windlas Biotech operates primarily in pharmaceutical CDMO services, trade generic brands, and over-the-counter (OTC) wellness products.

Where can investors inspect Windlas Biotech's statutory financial releases?

Investors can access complete audited quarterly statements and corporate disclosures on the official portals of the National Stock Exchange of India Limited (NSE) and BSE Limited.

Source: TradingView Reuters News Feed, National Stock Exchange of India, BSE Limited.